Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium

BACKGROUND: Bipolar disorder (BPD) is a widespread condition characterized by recurring states of mania and depression. Lithium, a direct inhibitor of glycogen synthase kinase 3 (GSK3) activity, and a mainstay in BPD therapeutics, has been proposed to target GSK3 as a mechanism of mood stabilization...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kaladchibachi, Sevag A, Doble, Brad, Anthopoulos, Norman, Woodgett, James R, Manoukian, Armen S
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2007
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1803776/
https://ncbi.nlm.nih.gov/pubmed/17295926
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1740-3391-5-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars